Sustained release subcutaneous delivery of BMS-686117, a GLP-1 receptor peptide agonist, via a zinc adduct

International Journal of Pharmaceutics

Volumn 374, Issue 1-2, 2009, Pages 46-52

  Qian, Feng ^a   Ni, Nina ^a   Burton, Lori S ^a   Wang, Yue Fen ^a   Desikan, Sridhar ^a   Hussain, Munir ^a   Smith, Ronald L ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

GLP 1; Spray drying; Subcutaneous injection; Sustained release; Zinc

Indexed keywords

BMS 686117; EDETIC ACID; POLYGLACTIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; ZINC ACETATE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG HALF LIFE; GLASS TRANSITION TEMPERATURE; MALE; NONHUMAN; PRIORITY JOURNAL; SPRAY DRYING; SUSTAINED DRUG RELEASE;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DOGS; HALF-LIFE; HYDROGEN-ION CONCENTRATION; INJECTIONS, SUBCUTANEOUS; LACTIC ACID; MALE; MICROSPHERES; OLIGOPEPTIDES; POLYGLYCOLIC ACID; RECEPTORS, GLUCAGON; SOLUBILITY; TIME FACTORS; TRANSITION TEMPERATURE; ZINC ACETATE;

EID: 67349098524     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.03.007     Document Type: Article

References (33)

1. Blanusa M., Varnai V.M., Piasek M., and Kostial K. Chelators as antidotes of metal toxicity: therapeutic and experimental aspects. Curr Med Chem. 12 (2005) 2771-2794
2. Bonaccio M., Ghaderi N., Borchardt D., and Dunn M.F. Insulin allosteric behavior: detection, identification, and quantification of allosteric states via 19F NMR. Biochemistry 44 (2005) 7656-7668
3. Christianson D.W. Structural biology of zinc. Adv. Protein Chem. 42 (1991) 281-355
4. Cooksley W.G. Peginterferon-alpha 2a for the treatment of hepatitis B infection. Expert. Opin. Pharmacother. 6 (2005) 1373-1380
5. Derjaguin B.V., and Landau L. Acta Physiochim. 14 (1941) 633
6. Drucker D.J. Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes. Curr. Pharm. Des. 7 (2001) 1399-1412
7. Elbrond B., Jakobsen G., Larsen S., Agerso H., Jensen L.B., Rolan P., Sturis J., Hatorp V., and Zdravkovic M. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 25 (2002) 1398-1404
8. Enyedy E.A., Horvath L., Gajda-Schrantz K., Galbacs G., and Kiss T. An in vitro study of interactions between insulin-mimetic zinc(II) complexes and selected plasma components. J. Inorg. Biochem. 100 (2006) 1936-1945
9. Garbayo E., Ansorena E., Lanciego J.L., Aymerich M.S., and Blanco-Prieto M.J. Sustained release of bioactive glycosylated glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres. Eur. J. Pharm. Biopharm. (2008)
10. Giddi H.S., Arunagirinathan M.A., and Bellare J.R. Self-assembled surfactant nano-structures important in drug delivery: a review. Indian J. Exp. Biol. 45 (2007) 133-159
11. Hadziyannis S.J., and Papatheodoridis G.V. Peginterferon-alpha2a (40 kDa) for chronic hepatitis C. Expert. Opin. Pharmacother. 4 (2003) 541-551
12. Holst J.J., and Orskov C. The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism. Diabetes 53 (2004) S197-S204
13. Jin T., Zhu J., Wu F., Yuan W., Geng L.L., and Zhu H. Preparing polymer-based sustained-release systems without exposing proteins to water-oil or water-air interfaces and cross-linking reagents. J. Control Release 128 (2008) 50-59
14. Kjems L.L., Holst J.J., Volund A., and Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52 (2003) 380-386
15. Larsen J., Hylleberg B., Ng K., and Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 24 (2001) 1416-1421
16. Loomans H.J., Hahn B.L., Li Q.Q., Phadnis S.H., and Sohnle P.G. Histidine-based zinc-binding sequences and the antimicrobial activity of calprotectin. J. Infect. Dis. 177 (1998) 812-814
17. Maa Y.F., and Prestrelski S.J. Biopharmaceutical powders: particle formation and formulation considerations. Curr. Pharm. Biotechnol. 1 (2000) 283-302
18. Miller D.J., and O'Dowd A. Vascular smooth muscle actions of carnosine as its zinc complex are mediated by histamine H(1) and H(2) receptors. Biochemistry (Moscow) 65 (2000) 798-806
19. Mok H., and Park T.G. Water-free microencapsulation of proteins within PLGA microparticles by spray drying using PEG-assisted protein solubilization technique in organic solvent. Eur. J. Pharm. Biopharm. (2008)
20. Nande V.S., Barabde U.V., Morkhade D.M., Joshi S.B., and Patil A.T. Investigation of PEGylated derivatives of rosin as sustained release film formers. AAPS PharmSciTech. 9 (2008) 105-111
21. Nourparvar A., Bulotta A., Di Mario U., and Perfetti R. Novel strategies for the pharmacological management of type 2 diabetes. Trends Pharmacol. Sci. 25 (2004) 86-91
22. Nyborg J.K., and Peersen O.B. That zincing feeling: the effects of EDTA on the behaviour of zinc-binding transcriptional regulators. Biochem. J. 381 (2004) e3-e4
23. Okada H., and Toguchi H. Biodegradable microspheres in drug delivery. Crit Rev. Ther. Drug Carrier Syst. 12 (1995) 1-99
24. Putney S.D., and Burke P.A. Improving protein therapeutics with sustained-release formulations. Nat. Biotechnol. 16 (1998) 153-157
25. Sadrzadeh N., Glembourtt M.J., and Stevenson C.L. Peptide drug delivery strategies for the treatment of diabetes. J. Pharm. Sci. 96 (2007) 1925-1954
26. Schmidt P.G., Campbell K.M., Hinds K.D., and Cook G.P. PEGylated bioactive molecules in biodegradable polymer microparticles. Expert. Opin. Biol. Ther. 7 (2007) 1427-1436
27. Shi Y., and Li L. Current advances in sustained-release systems for parenteral drug delivery. Expert. Opin. Drug Deliv. 2 (2005) 1039-1058
28. Tamber H., Johansen P., Merkle H.P., and Gander B. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv. Drug Deliv. Rev. 57 (2005) 357-376
29. Verwey E.J.W., and Overbeek J.Th.G. Theory of Stability of Lyophobic Colloids (1948), Elsevier, Amsterdam
30. Wang Y., Li Y., Wang Q., Wu J., and Fang X. Pharmacokinetics and biodistribution of paclitaxel-loaded pluronic P105/L101 mixed polymeric micelles. Yakugaku Zasshi 128 (2008) 941-950
31. Xiong M.P., Yanez J.A., Remsberg C.M., Ohgami Y., Kwon G.S., Davies N.M., and Forrest M.L. Formulation of a geldanamycin prodrug in mPEG-b-PCL micelles greatly enhances tolerability and pharmacokinetics in rats. J. Control Release 129 (2008) 33-40
32. Ye M., Bhat G., Johnston K.A., Tan H., and Garnick M. Proprietary Rel-Ease drug delivery technology: opportunity for sustained delivery of peptides, proteins and small molecules. Expert. Opin. Drug Deliv. 3 (2006) 663-675
33. Yu L., Chang G.T., Zhang H., and Ding J.D. Injectable block copolymer hydrogels for sustained release of a PEGylated drug. Int. J. Pharm. 348 (2008) 95-106